Keep Up With the Latest on COVID-19 Monoclonal Antibodies

Bamlanivimab/etesevimab will be the third monoclonal antibody option authorized to treat COVID-19.

This combo joins bamlanivimab and casirivimab/imdevimab as another single-dose IV infusion. And more are in the works.

Recall that these "mabs" block SARS-CoV-2 from entering cells.

Get unlimited access through an Enterprise license

Hospital Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals